{
  "id": 17783694,
  "title": "Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trial",
  "url": "https://urgent.news/2026/11/02/neoadjuvant-botensilimab-with-or-without-balstilimab-in-pmmr-and-dmmr",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-02T00:00:00.000Z",
  "source": {
    "name": "Nature Medicine",
    "slug": "nature-medicine",
    "url": "https://www.nature.com/articles/s41591-026-04710-1"
  },
  "original_language": "en",
  "account": null,
  "summary": "Nature Medicine, Published online: 02 November 2026; doi:10.1038/s41591-026-04710-1 In the phase 2 UNICORN trial, a short course of neoadjuvant botensilimab and balstilimab achieved the primary endpoint of pathological major response rate in patients with pMMR or dMMR colon cancer.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}